Aaraj Mahmoud Al, Boorinie Mustafa, Salfity Louay, Eweiss Ahmed
General Surgery Department, Royal Bolton NHS Trust, Bolton, UK.
General Surgery Department, Blackpool Teaching Hospital NHS Foundation Trust, Blackpool, UK.
Indian J Otolaryngol Head Neck Surg. 2023 Jun 10;75(4):1-5. doi: 10.1007/s12070-023-03938-4.
Different modalities of treatment have been suggested in the treatment for post COVID-19 olfactory dysfunction (OD). Starting with lifestyle modification, smoking cessation, for example, was shown to improve the symptoms for patients with OD. Intranasal and oral corticosteroids have been described in the literature for the treatment of OD. In this review, we are looking at a novel intervention using platelet-rich plasma injection into the nasal cleft for treatment of post COVID-19 infection olfactory dysfunction.
A literature search was done using the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) 2020 Guidelines, the databases of PMC, Medline, CINAHL, Wiley online library were searched from their year of inception until February 2023. Search terms were used and included a combination of the following keywords; "platelet-rich plasma", "platelet rich plasma", "PRP", "Anosmia", "olfactory dysfunction" and "COVID".
The four studies in this review included a total of 238 adult patients who presented with olfactory dysfunction. The studies were heterogenic in terms of follow up period which was not long enough through all the included studies. Additionally, different protocol of injecting was seen in different studies.
Injecting PRP for treatment of COVID-19 induced olfactory dysfunction is a safe technique with what seems like promising initial results with low complication rate. However, there are not enough studies assessing its effectiveness compared to other treatment modalities. Further randomized controlled trials with shared protocol are needed to establish further understanding of its role in treatment of COVID-19 induced OD.
针对新冠病毒感染后嗅觉功能障碍(OD)的治疗,已提出了不同的治疗方式。从改变生活方式开始,例如戒烟,已证明对嗅觉功能障碍患者的症状有改善作用。文献中已描述了鼻内和口服皮质类固醇用于治疗嗅觉功能障碍。在本综述中,我们着眼于一种新型干预措施,即向鼻裂注射富含血小板血浆以治疗新冠病毒感染后嗅觉功能障碍。
按照系统评价和荟萃分析的首选报告项目(PRISMA)2020指南进行文献检索,检索了PMC、Medline、CINAHL、Wiley在线图书馆数据库,从其创建年份至2023年2月。使用了检索词,包括以下关键词的组合:“富含血小板血浆”、“富血小板血浆”、“PRP”、“嗅觉丧失”、“嗅觉功能障碍”和“新冠”。
本综述中的四项研究共纳入了238例出现嗅觉功能障碍的成年患者。这些研究在随访期方面存在异质性,且所有纳入研究的随访期都不够长。此外,不同研究中注射方案也有所不同。
注射PRP治疗新冠病毒感染引起的嗅觉功能障碍是一种安全的技术,初步结果似乎很有前景,并发症发生率低。然而,与其他治疗方式相比,评估其有效性的研究还不够。需要进一步开展采用共享方案的随机对照试验,以进一步了解其在治疗新冠病毒感染引起的嗅觉功能障碍中的作用。